American Heart Journal
Volume 145, Issue 6 , Pages 933-935 , June 2003

Atheromatous showers, periprocedural myocardial infarction, and fatality

  • Michael H. Yen, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • Eric J. Topol, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • Corresponding Author InformationReprint requests: Eric J. Topol, MD, Cleveland Clinic Foundation, Department of Cardiovascular Medicine/F25, 9500 Euclid Ave, Cleveland, OH 44195, USA.

References 

  1. Baim DS, Wahr D, George B, et al.  Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105:1285–1290
  2. Kotani J, Nanto S, Mintz GS, et al.  Plaque gruel of atheromatous coronary lesion may contribute to the no-reflow phenomenon in patients with acute coronary syndrome. Circulation. 2002;106:1672–1677
  3. Bonderman D, Teml A, Jakowitsch J, et al.  Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood. 2002;99:2794–2800
  4. Penn MS, Topol EJ. Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. Circ Res. 2001;89:1–2
  5. Chew DP, Bhatt DL, Robbins MA, et al.  Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 2001;104:992–997
  6. Califf RM, Abdelmeguid AE, Kuntz RE, et al.  Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241–251
  7. Fuchs S, Kornowski R, Mehran R, et al.  Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol. 2000;85:1077–1082
  8. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting). Lancet. 1998;352:87–92
  9. Kini A, Kini S, Marmur JD, et al.  Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. Catheter Cardiovasc Interv. 1999;48:123–129
  10. Abdelmeguid AE, Topol EJ. The myth of the myocardial “infarctlet” during percutaneous coronary revascularization procedures. Circulation. 1996;94:3369–3375
  11. Elliott JM, Berdan LG, Holmes DR, et al.  One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I). Circulation. 1995;91:2158–2166
  12. Ellis SG, Chew D, Chan A, et al.  Death following creatine kinase-MB elevation after coronary intervention (identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy). Circulation. 2002;106:1205–1210
  13. Ghazzal Z, Ashfaq S, Morris DC, et al.  Prognostic implication of creatine kinase release after elective precutaneous coronary intervention in the pre-IIb/IIIa antagonist era. Am Heart J. 2003;145:1006–1012
  14. Topol EJ, Lincoff AM, Kereiakes DJ, et al.  Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 2002;113:1–6
  15. Abdelmeguid AE, Topol EJ, Whitlow PL, et al.  Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation. 1996;94:1528–1536
  16. Topol EJ, Mark DB, Lincoff AM, et al.  Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting (results from a multicentre randomised trial. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting). Lancet. 1999;354:2019–2024

PII: S0002-8703(03)00096-6

doi: 10.1016/S0002-8703(03)00096-6

American Heart Journal
Volume 145, Issue 6 , Pages 933-935 , June 2003

Article Tools